Dr. Skarbnik on Triplet Combination Strategies for Hematologic Malignancies

Alan Skarbnik, MD
Published: Thursday, Mar 15, 2018



Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, Department of Lymphoma, John Theurer Cancer Center, discusses triplet combinations in hematologic malignancies.

An important consideration when combining agents is overlapping toxicities, explains Skarbnik. For example, combining ipilimumab (Yervoy) with a PD-1 inhibitor could potentially increase the toxicity since both agents are immune mediated, which could cause more immune-related adverse events.

Toxicity associated with combinations is a cost that patients pay for more efficacy across all cancer types, says Skarbnik. Adding a third drug may be complicated but it is possible. There has been success with triplet sequential therapy in hematologic malignancies, and it did not demonstrate any unexpected added toxicity.
 


Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, Department of Lymphoma, John Theurer Cancer Center, discusses triplet combinations in hematologic malignancies.

An important consideration when combining agents is overlapping toxicities, explains Skarbnik. For example, combining ipilimumab (Yervoy) with a PD-1 inhibitor could potentially increase the toxicity since both agents are immune mediated, which could cause more immune-related adverse events.

Toxicity associated with combinations is a cost that patients pay for more efficacy across all cancer types, says Skarbnik. Adding a third drug may be complicated but it is possible. There has been success with triplet sequential therapy in hematologic malignancies, and it did not demonstrate any unexpected added toxicity.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
Publication Bottom Border
Border Publication
x